ClinicalTrials.gg
CompletedNCT05248893Updated Sep 25, 2026Results posted

A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

A Phase 3 interventional study of AGN-151586 in Glabellar Lines, sponsored by AbbVie. Completed at 43 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Updated Sep 25, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
992
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with botulinum toxin. The primary purpose of this study is to evaluate the safety of AGN-151586 over up to three treatments of the study drug to improve the appearance of glabellar lines.

AGN-151586 is an investigational product being developed for the treatment of GL. Around 940 to 1100 adult participants with moderate to severe GL will be enrolled in the study in approximately 45 sites in the United States.

This is an open-label study in which all participants will receive 5 intramuscular AGN-151586 injections to the glabellar complex on Day 1. Participants meeting retreatment criteria may receive up to 2 additional doses of treatment during the study.

Participants will attend regular visits during the study at a study site. The effect of the treatment will be checked by medical assessments, blood tests, telephone calls, questionnaires and checking for side effects.

02

Conditions studied

  • Glabellar Lines

Keywords

  • Glabellar Lines
  • AGN-151586
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be able to accurately assess their facial lines without the use of eyeglasses (contact lens use is acceptable).
  • Participant must have moderate or severe Glabellar Lines at maximum frown as assessed by both the investigator and participant using the Facial Wrinkle Scale (FWS) at Screening and Baseline Day 1 visit.

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled systemic disease.
  • Presence or history of any medical condition that may place the subject at increased risk following exposure to AGN-151586 or interfere with the study evaluation, including:

    • Diagnosed myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis, or any other significant disease that might interfere with neuromuscular function
    • History of facial nerve palsy
    • Infection or dermatological condition at the treatment injection sites
    • Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, excessively photodamaged skin, or the inability to substantially lessen facial lines even by physically spreading them apart
    • Any eyebrow or eyelid ptosis at screening or Baseline Day 1 visit as determined by the investigator
  • History of known immunization to any botulinum toxin serotype.
  • Participants who have reported use of any botulinum neurotoxin of any serotype (including any botulinum neurotoxin product) for aesthetic treatment within the last 6 months prior to screening and for therapeutic treatment within the last 12 months prior to study drug administration.
  • Tattoos, jewelry, or clothing which obscure the glabellar area and cannot be removed.
  • Anticipated need for surgery or overnight hospitalization during the study.
  • History of surgical procedures on forehead and/or periorbital areas or affecting these areas including any lifting procedure (e.g., rhinoplasty, facial lift, suture lift, thread lift, brow lift, eyelid and/or eyebrow surgery).
  • History of periorbital, mid-facial, or upper-facial treatment with semi-permanent or permanent soft tissue fillers (e.g., poly-L-lactic acid, polyalkylimide, polymethylmethacrylate, polytetrafluoroethylene, and silicone), synthetic implantation and/or autologous fat transplantation.
  • Known active severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection.
  • Female subject who is pregnant or breastfeeding, and is considering becoming pregnant or donating eggs during the study or for approximately 30 days after the last dose of study drug or until the end of study, whichever is longer.
  • Participant who has been treated with any investigational drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study or was previously enrolled in this study.
  • Anticipated need for treatment with botulinum neurotoxin of any serotype for any reason during the study (other than study drug).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
992 participants (actual)

Study arms

  • Experimental
    AGN-151586

    Participants will receive 5 intramuscular injections in the glabellar complex on Day 1 (Dose 1). Based on meeting the retreatment criteria, the participant may receive up to 2 additional doses of open-label treatments.

    Drug: AGN-151586

Interventions

  • Powder for Solution for Intramuscular Injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.

    Time frame: Day 1 (Baseline) to Day 126

  2. Participants With Post-Baseline Potentially Clinically Important (PCI) Values for Systolic Blood Pressure

    The number of subjects with at least 1 PCI post-baseline value during the study are reported. A post-baseline value was considered PCI if it met both the observed-value and the change-from-baseline criteria.

    Time frame: Day 1 (Baseline) to Day 126

  3. Participants With Post-Baseline PCI Values for Diastolic Blood Pressure

    The number of subjects with at least 1 PCI post-baseline value during the study are reported. A post-baseline value was considered PCI if it met both the observed-value and the change-from-baseline criteria.

    Time frame: Day 1 (Baseline) to Day 126

  4. Participants With Post-Baseline PCI Values for Heart Rate

    The number of subjects with at least 1 PCI post-baseline value during the study are reported. A post-baseline value was considered PCI if it met both the observed-value and the change-from-baseline criteria.

    Time frame: Day 1 (Baseline) to Day 126

  5. Participants With Post-baseline PCI Values in Temperature

    Only the observed-value criterion (\>= 38.3 C) was needed for temperature to be potentially clinically important (but must be more extreme than baseline, if baseline was present).

    Time frame: Day 1 (Baseline) to Day 126

  6. Participants With Post-baseline PCI Values in Electrocardiogram Parameters

    12-lead resting ECGs will be recorded. Parameters include heart rate, PR interval, QT interval, QRS duration, and QT interval corrected using Fridericia's formula (QTcF). A post-baseline value is considered potentially clinically important if it meets either the observed-value or the change-from-baseline criteria (but must be more extreme than baseline if baseline is present).

    Time frame: Day 1 (Baseline) to Day 126

  7. Presence of Binding and Neutralizing Antidrug Antibodies to AGN-151586

    Blood samples for immunogenicity testing were collected from participants treated with AGN-151586 at predetermined timepoints. Collected samples were processed to yield serum for detection of binding and neutralizing antibodies to AGN-151586.

    Time frame: Day 1 (Baseline) to Day 126

07

Results

Posted Sep 25, 2026

Participant flow

A total of 992 participants (ITT population) were enrolled at 41 sites in the USA and Puerto Rico. A total of 985 participants received at least 1 dose of AGN-151586; 916 participants received at least 2 doses, and 846 participants received 3 doses. The safety population included 985 participants who received at least one dose of AGN-151586.

All Enrolled Participants (ITT)
Participant flow — All Enrolled Participants (ITT)
MilestoneAll Enrolled Participants (ITT)AGN-151586 (Dose 1)AGN-151586 (Dose 2)AGN-151586 (Dose 3)
Started992000
Completed985000
Not completed7000
Withdrew: Lost to follow-up2000
Withdrew: Withdrawal by subject4000
Withdrew: Other, not specified1000
AGN-151586 (Dose 1)
Participant flow — AGN-151586 (Dose 1)
MilestoneAll Enrolled Participants (ITT)AGN-151586 (Dose 1)AGN-151586 (Dose 2)AGN-151586 (Dose 3)
Started098500
Completed091600
Not completed06900
Withdrew: Lost to follow-up01100
Withdrew: Withdrawal by subject03500
Withdrew: Withdrawal by subject due to adverse event0400
Withdrew: Covid-19 infection0100
Withdrew: Other, not specified01800
AGN-151586 (Dose 2)
Participant flow — AGN-151586 (Dose 2)
MilestoneAll Enrolled Participants (ITT)AGN-151586 (Dose 1)AGN-151586 (Dose 2)AGN-151586 (Dose 3)
Started009160
Completed008480
Not completed00680
Withdrew: Lost to follow-up00140
Withdrew: Withdrawal by subject00290
Withdrew: Withdrawal by subject due to adverse event0040
Withdrew: Covid-19 infection0010
Withdrew: Other, not specified00200
AGN-151586 (Dose 3)
Participant flow — AGN-151586 (Dose 3)
MilestoneAll Enrolled Participants (ITT)AGN-151586 (Dose 1)AGN-151586 (Dose 2)AGN-151586 (Dose 3)
Started000846
Completed000836
Not completed00010
Withdrew: Lost to follow-up0007
Withdrew: Withdrawal by subject0003

Outcome measures

PrimaryNumber of Participants With Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.

Time frame:
Day 1 (Baseline) to Day 126
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsAGN-151586 (Dose 1)AGN-151586 (Dose 2)AGN-151586 (Dose 3)Any AGN-151586
Number of Participants With Adverse Events213174128374
PrimaryParticipants With Post-Baseline Potentially Clinically Important (PCI) Values for Systolic Blood Pressure

The number of subjects with at least 1 PCI post-baseline value during the study are reported. A post-baseline value was considered PCI if it met both the observed-value and the change-from-baseline criteria.

Time frame:
Day 1 (Baseline) to Day 126
Reported as:
Number · participants
Participants With Post-Baseline Potentially Clinically Important (PCI) Values for Systolic Blood Pressure
participantsAGN-151586 (Dose 1)AGN-151586 (Dose 2)AGN-151586 (Dose 3)Any AGN-151586
>= 160 mmHg and Increase of >=20 mmHg561419
<= 90 mmHg and Decrease of >= 20 mmHg13610
PrimaryParticipants With Post-Baseline PCI Values for Diastolic Blood Pressure

The number of subjects with at least 1 PCI post-baseline value during the study are reported. A post-baseline value was considered PCI if it met both the observed-value and the change-from-baseline criteria.

Time frame:
Day 1 (Baseline) to Day 126
Reported as:
Number · participants
Participants With Post-Baseline PCI Values for Diastolic Blood Pressure
participantsAGN-151586 (Dose 1)AGN-151586 (Dose 2)AGN-151586 (Dose 3)Any AGN-151586
>= 100 mmHg and Increase of >= 15 mmHg36916
<= 50 mmHg and Decrease of >= 15 mmHg1315
PrimaryParticipants With Post-Baseline PCI Values for Heart Rate

The number of subjects with at least 1 PCI post-baseline value during the study are reported. A post-baseline value was considered PCI if it met both the observed-value and the change-from-baseline criteria.

Time frame:
Day 1 (Baseline) to Day 126
Reported as:
Number · participants
Participants With Post-Baseline PCI Values for Heart Rate
participantsAGN-151586 (Dose 1)AGN-151586 (Dose 2)AGN-151586 (Dose 3)Any AGN-151586
>= 110 beats/minute and Increase of >= 15 beats/minute45410
<= 50 beats/minute and Decrease of >= 15 beats/minute3378
PrimaryParticipants With Post-baseline PCI Values in Temperature

Only the observed-value criterion (\>= 38.3 C) was needed for temperature to be potentially clinically important (but must be more extreme than baseline, if baseline was present).

Time frame:
Day 1 (Baseline) to Day 126
Reported as:
Count of participants · Participants
Participants With Post-baseline PCI Values in Temperature
ParticipantsAGN-151586 (Dose 1)AGN-151586 (Dose 2)AGN-151586 (Dose 3)Any AGN-151586
Participants With Post-baseline PCI Values in Temperature0000
PrimaryParticipants With Post-baseline PCI Values in Electrocardiogram Parameters

12-lead resting ECGs will be recorded. Parameters include heart rate, PR interval, QT interval, QRS duration, and QT interval corrected using Fridericia's formula (QTcF). A post-baseline value is considered potentially clinically important if it meets either the observed-value or the change-from-baseline criteria (but must be more extreme than baseline if baseline is present).

Time frame:
Day 1 (Baseline) to Day 126
Reported as:
Number · participants
Participants With Post-baseline PCI Values in Electrocardiogram Parameters
participantsAGN-151586 (Dose 1)AGN-151586 (Dose 2)AGN-151586 (Dose 3)Any AGN-151586
QRS Interval >= 150 msec1111
PR Interval >= 250 msec1011
QTcB > 500 msec or Increase of > 60 msec3238
QTcF > 500 msec or Increase of > 60 msec0000
PrimaryPresence of Binding and Neutralizing Antidrug Antibodies to AGN-151586

Blood samples for immunogenicity testing were collected from participants treated with AGN-151586 at predetermined timepoints. Collected samples were processed to yield serum for detection of binding and neutralizing antibodies to AGN-151586.

Time frame:
Day 1 (Baseline) to Day 126
Reported as:
Number · participants
Presence of Binding and Neutralizing Antidrug Antibodies to AGN-151586
participantsAGN-151586 (1 Dose)AGN-151586 (2 Doses)AGN-151586 (3 Doses)Any AGN-151586
Binding Antibodies (AGN-151586)0022
Neutralizing Antibodies (AGN-151586)——11

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from enrollment to end of study. Of the 992 participants enrolled, 7 did not receive treatment and were discontinued during the screening period. The median time participants were followed was 12.0 days for the untreated group; 57.0 days for the AGN-151586 (1 Dose) group; 101.0 days for the AGN-151586 (2 Doses) group; and 138.0 days for the AGN-151586 (3 Doses) group.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Not Treated0/7 (0%)0/7 (0%)0/7 (0%)
AGN-151586 (1 Dose)0/69 (0%)3/69 (4.3%)11/69 (15.9%)
AGN-151586 (2 Doses)0/70 (0%)0/70 (0%)9/70 (12.9%)
AGN-151586 (3 Doses)0/846 (0%)4/846 (0.5%)147/846 (17.4%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventNot TreatedAGN-151586 (1 Dose)AGN-151586 (2 Doses)AGN-151586 (3 Doses)
BILIARY DILATATIONHepatobiliary disorders0/71/690/700/846
CHOLECYSTITIS ACUTEHepatobiliary disorders0/71/690/700/846
DEVICE RELATED INFECTIONInfections and infestations0/71/690/700/846
JAW FRACTUREInjury, poisoning and procedural complications0/71/690/700/846
RIB FRACTUREInjury, poisoning and procedural complications0/71/690/700/846
ROAD TRAFFIC ACCIDENTInjury, poisoning and procedural complications0/71/690/700/846
SKIN LACERATIONInjury, poisoning and procedural complications0/71/690/700/846
SPINAL COLUMN INJURYInjury, poisoning and procedural complications0/71/690/700/846
OBSTRUCTIVE PANCREATITISGastrointestinal disorders0/70/690/701/846
CHOLELITHIASISHepatobiliary disorders0/70/690/701/846
Most frequent other events
Most frequent other events
EventNot TreatedAGN-151586 (1 Dose)AGN-151586 (2 Doses)AGN-151586 (3 Doses)
HEADACHENervous system disorders0/74/696/7077/846
INJECTION SITE PAINGeneral disorders0/74/691/7044/846
COVID-19Infections and infestations0/73/692/7046/846

Baseline characteristics

Baseline analyses were performed on the ITT Population, consisting of all enrolled subjects (N=992).

Age, Categorical
Age, Categorical(Participants)AGN-151586
<=18 years0
Between 18 and 65 years899
>=65 years93
Age, Continuous
Age, Continuous(Years)AGN-151586
Mean49.3 ± 11.52
Sex: Female, Male
Sex: Female, Male(Participants)AGN-151586
Female852
Male140
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AGN-151586
Hispanic or Latino238
Not Hispanic or Latino754
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AGN-151586
American Indian or Alaska Native16
Asian22
Native Hawaiian or Other Pacific Islander2
Black or African American65
White876
More than one race11
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)AGN-151586
Puerto Rico43
United States949
08

Study locations

43 sites
  • Skin Wellness Dermatology - Homewood /ID# 241233
    Birmingham, Alabama 35209-8314, United States
  • Advanced Research Associates - Glendale /ID# 232245
    Glendale, Arizona 85308, United States
  • Skin Care and Laser Physicians of Beverly Hills /ID# 241237
    Los Angeles, California 90069, United States
  • The Eye Research Foundation /ID# 232229
    Newport Beach, California 92663-3637, United States
  • Cosmetic Laser Dermatology /ID# 243513
    San Diego, California 92121-2119, United States
  • UC San Diego Health - University Center Lane - La Jolla /ID# 241243
    San Diego, California 92122-1013, United States
  • Ava T. Shamban MD - Santa Monica. /ID# 241246
    Santa Monica, California 90404-2208, United States
  • Art of Skin MD /ID# 241244
    Solana Beach, California 92075-2228, United States
  • Moradi MD /ID# 241242
    Vista, California 92083-6030, United States
  • AboutSkin Research, LLC /ID# 241702
    Greenwood Village, Colorado 80111, United States
  • Susan H. Weinkle MD /ID# 233835
    Bradenton, Florida 34209-5642, United States
  • Skin Research Institute LLC /ID# 232240
    Coral Gables, Florida 33146-1837, United States
  • Skin and Cancer Associates, LLP /ID# 232228
    Miami, Florida 33137-3254, United States
  • ForCare Clinical Research /ID# 241229
    Tampa, Florida 33613-1244, United States
  • Hamilton Research, LLC /ID# 241232
    Alpharetta, Georgia 30022, United States
  • Atlanta Biomedical Clinical Research /ID# 241258
    Atlanta, Georgia 30331-2160, United States
  • Meridian Clinical Research Dermatology /ID# 241234
    Savannah, Georgia 31406-2632, United States
  • DeNova Research /ID# 232231
    Chicago, Illinois 60611, United States
  • Advanced Dermatology /ID# 241252
    Lincolnshire, Illinois 60069, United States
  • Laser and Skin Surgery Center of Indiana /ID# 233834
    Indianapolis, Indiana 46260-2386, United States
  • Coleman Center For Cosmetic Dermatologic Surgery /ID# 232230
    Metairie, Louisiana 70006, United States
  • Etre Cosmetic Dermatology and Laser Center /ID# 232235
    New Orleans, Louisiana 70130-4353, United States
  • Visage Dermatology and Aesthetic Center /ID# 241248
    Largo, Maryland 20774-5341, United States
  • Rkmd, Llc /Id# 241239
    North Bethesda, Maryland 20852-3093, United States
  • Michigan Center for Research Company /ID# 241255
    Clarkston, Michigan 48346, United States
  • Rao Dermatology /ID# 243515
    Atlantic Highlands, New Jersey 07716-1241, United States
  • image Dermatology, P.C. /ID# 241227
    Montclair, New Jersey 07042, United States
  • The Rejuva Center /ID# 244285
    Latham, New York 12110, United States
  • Mariwalla Dermatology /ID# 241240
    West Islip, New York 11795-4916, United States
  • Northwest Dermatology Institute /ID# 233498
    Portland, Oregon 97210-2859, United States
  • Perelman Center for Advanced Medicine - /ID# 243966
    Philadelphia, Pennsylvania 19104-5127, United States
  • Sherman Aesthetic Center /ID# 241247
    Nashville, Tennessee 37205-2205, United States
  • Tennessee Clinical Research Center /ID# 241254
    Nashville, Tennessee 37215-2885, United States
  • DermResearch, Inc. Austin, TX /ID# 241228
    Austin, Texas 78759, United States
  • Bellaire Dermatology Associates /ID# 232243
    Bellaire, Texas 77401, United States
  • J&S Studies, Inc. /ID# 241236
    College Station, Texas 77845-3898, United States
  • Dallas Center for Dermatology and Aesthetics /ID# 241245
    Dallas, Texas 75225-6203, United States
  • Swinyer-Woseth Dermatology /ID# 241250
    Salt Lake City, Utah 84117-4209, United States
  • The Education & Research Foundation, Inc. /ID# 241225
    Lynchburg, Virginia 24501-1403, United States
  • Premier Clinical Research /ID# 233836
    Spokane, Washington 99202, United States
  • EthiQ2 Research, LLC /ID# 241256
    Brookfield, Wisconsin 53005, United States
  • Santa Cruz Behavioral (SCB) Research Center /ID# 241226
    Bayamón, 00961-6910, Puerto Rico
  • Jose Raul Montes Eyes & Facial Rejuvenation-Torre Medica Aux /ID# 241241
    San Juan, 00917, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Jun 2023, 16 months.

Results were first posted in Sep 2026, 3 years 2 months after primary completion. A results delay was requested in May 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2022
First posted
Feb 21, 2022
StartActual
Feb 25, 2022
Primary completionActual
Jun 26, 2023
CompletionActual
Jun 26, 2023
Results delay requested
May 28, 2024
Results first posted
Sep 25, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05248893
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 21, 2022
Start date
Feb 25, 2022
Primary completion
Jun 26, 2023
Completion
Jun 26, 2023
Results posted
Sep 25, 2026
Last update
Sep 25, 2026

Study contacts

ABBVIE INC.
study director · Allergan

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: trenibotulinumtoxinE

Start the discussion